Floatz logo

Activated T Cells

Recurrent Glioblastoma

Jeremy Rudnick, M.DCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

353 Active assets in the Recurrent Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Activated T Cells is also rated in:

relapsing-remitting multiple sclerosisDormant
CC
Indicative ·
45 / 100
View asset →
Chronic Lymphocytic LeukemiaDormant
CC
Indicative ·
40 / 100
View asset →
colorectal carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →